Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
- PMID: 39354432
- PMCID: PMC11443928
- DOI: 10.1186/s12885-024-12935-x
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer
Abstract
Background: Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly or three-weekly irinotecan regimens have been adopted, however, the optimal dose and schedule is not defined. In our institution, we use a bi-weekly regimen of irinotecan. In this study, we aimed to investigate the safety and efficacy of the bi-weekly irinotecan in the second- or third-line treatment of SCLC patients.
Methods: The study population consisted of advanced stage SCLC patients who were followed at Hacettepe University Cancer Institute between January 2007 and March 2021 and received salvage irinotecan 180 mg/m2 every two weeks, following progression after platinum-etoposide treatment.
Results: One hundred patients were included. At diagnosis, nineteen patients (19%) had limited stage and 81 patients (81%) had extensive stage SCLC. Objective response rates (ORR) were 44.6% and 46.2% for patients who received irinotecan treatment in second line, and in third line, respectively. Seventeen percent of all the patients had grade 3 and above adverse events during irinotecan treatment. In our study, 45.8% of patients were able to complete at least 6 cycles of irinotecan treatment and 69.8% were able to receive at least 3 cycles of irinotecan treatment without any dose interruption or reduction.
Conclusions: Irinotecan 180 mg/m2 every two weeks appears to be safe and effective in the 2nd- and 3rd-line treatment of advanced stage SCLC. Bi-weekly administration allows G-CSF prophylaxis in between doses, leading to an uninterrupted administration.
Keywords: Bi-weekly administration; Irinotecan; Small cell lung cancer; Tolerability.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14. Lancet Oncol. 2016. PMID: 27312053 Clinical Trial.
-
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25. Clin Lung Cancer. 2017. PMID: 27867001
-
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.Cancer. 2010 May 15;116(10):2409-15. doi: 10.1002/cncr.25076. Cancer. 2010. PMID: 20225329 Clinical Trial.
-
Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.J BUON. 2021 Jan-Feb;26(1):79-86. J BUON. 2021. PMID: 33721436
-
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675546 Free PMC article.
References
-
- Hansen HH. Management of small-cell cancer of the lung. The Lancet. 1992;339(8797):846–9. - PubMed
-
- Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23(11):1697–9. - PubMed
-
- Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer. 2008;113(9):2518–23. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical